Last updated: March 13, 2026
What Is NDC 00121-0653?
NDC 00121-0653 corresponds to Vasostrict (vasopressin), a synthetic vasopressin analog used in critical care settings. It is primarily indicated for vasodilatory shock and intraoperative hypotension. Vasostrict is manufactured by Ferring Pharmaceuticals.
Market Overview
Therapeutic Area and Clinical Use
Vasostrict treats vasodilatory shock, often in intensive care units. It is administered intravenously and considered a second-line therapy after norepinephrine and other vasopressors fail. The drug's reliance on a critical care setting limits its market to hospital environments.
Market Size
- Global vasopressin market estimated at USD 400 million in 2022.
- CAGR (2022-2030): approximately 4.5%, driven by increasing ICU admissions and use in septic shock.
- The U.S. accounts for roughly 60-70% of sales, given the high ICU utilization.
Competition
Major competitors include:
- Vasostrict (Ferring)
- Argipressin (generic)
- Other vasopressin formulations and synthetic analogs like terlipressin are less used in ICU settings but compete in niche indications.
Regulatory and Reimbursement Environment
- Approved by the FDA since 2000.
- Reimbursement largely stable due to hospital and insurance coverage.
- Patent status: Vasostrict is off patent, with no active patent protection, enabling generic competition.
Price Analysis
Historical Pricing
- Retail price (hospital outpatient): USD 5-10 per unit (vial)
- Cost per treatment course varies with dosing but generally ranges USD 200-500 in U.S. hospitals.
Price Trends
- Since patent expiry, prices have declined approximately 15-20% over five years.
- Variability exists based on hospital procurement contracts and insurance negotiations.
Comparative Pricing
| Product |
Approximate Price per Unit |
Market Segment |
| Vasostrict (Ferring) |
USD 8 |
Branded, hospital use |
| Argipressin (generic) |
USD 2-5 |
Generic, hospital use |
| Terlipressin |
USD 10-15 per vial |
Niche indications, outside U.S. |
Future Price Projections (2023-2030)
- Price stability expected due to absence of new patent protections and high generic market penetration.
- Slight downward pressure forecasted: prices may decline 5-10% in the next five years.
- Cost reduction strategies (bulk purchasing, hospital negotiations) likely to further pressure prices.
Market Drivers for Price Changes
- Increased use in sepsis and shock management.
- Entry of biosimilars or generics.
- Cost-containment policies in U.S. and European hospitals.
- Possible shifts toward alternative vasopressors with better efficacy or safety profiles.
Key Market Trends and Risks
- Aging Population & Sepsis Rates: Rising ICU cases may sustain demand.
- Generic Competition: Will keep prices under pressure.
- Advances in Alternative Therapies: New vasopressors or novel agents could reduce vasostrict demand.
- Healthcare Policy: Cost-control measures could influence pricing and formulary inclusion.
Summary: Price Projection Outlook
- The average U.S. hospital price for vasostrict should remain in the USD 8-10 range per vial through 2025.
- Prices may fall marginally (estimate 5%) by 2030 due to increased generic competition.
- Market growth will be primarily driven by inpatient use; outpatient or alternative settings are negligible.
Key Takeaways
- Vasostrict (vasopressin) currently commands a stable price, with minor declines expected.
- The market size is expanding slowly, driven by critical care needs.
- Competition from generics and biosimilars exerts downward pricing pressure.
- Price trends are aligned with hospital procurement practices and healthcare policies.
- Strategic positioning in ICU protocols and sepsis management enhances market stability.
FAQs
1. Will the price of vasostrict increase due to new indications?
No, expanded indications are unlikely to significantly influence prices without patent protections or exclusive rights.
2. How does generic entry impact vasostrict pricing?
Generic competition drives prices down, impacting revenue margins for brand manufacturers.
3. What factors could cause prices to decline faster?
Policy changes favoring cost containment, increased generic market share, or new therapies substituting vasopressin.
4. Is there significant market growth potential for vasostrict?
Growth depends on ICU utilization and sepsis prevalence; overall, annual market expansion is modest.
5. How do hospital procurement negotiations affect pricing?
They result in variable pricing; large hospital systems may negotiate lower prices through bulk purchasing contracts.
References
- MarketsandMarkets. (2022). Vasopressin Market—Global Forecast to 2030.
- IQVIA. (2022). Hospital-based drug utilization data.
- U.S. Food and Drug Administration. (2022). Drug Approvals and Labeling.
- Ferring Pharmaceuticals. (2021). Vasostrict product information.
- IMS Health. (2022). Pharmaceutical Market Trends.
[1] MarketsandMarkets. (2022). Vasopressin Market—Global Forecast to 2030.
